The Market Herald - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • MGC Pharmaceuticals (MXC) completes its in-vitro pre-clinical study on its anti-inflammatory test drug, CimetrA
  • The company says the study confirms previous trial results that showed CimetrA significantly decreases inflammation
  • MGC Co-Founder and Managing Director Roby Zomer says the completion of the study advances the company’s understanding of CimetrA
  • The new study results will form part of MXCs application to the US FDA to register CimetrA as an Investigational New Drug to treat COVID-19 and other inflammatory conditions
  • MXC shares are trading at 0.8 cents at 3:27 pm

MGC Pharmaceuticals (MXC) has completed an in-vitro pre-clinical study on its CimetrA drug to explore its anti-inflammatory effects on human Peripheral Blood Mononuclear Cells (PBMC).

MGC pharmaceuticals is a European-based pharmaceutical company specialising in the production and development of plant-inspired medicines.

The new study results matched previous reports that suggest the administration of CrimetrA before and during Lipopolysaccharide (LPS) stimulation will produce an immune response that decreases the IL-32 mRNA protein.

The IL-32 mRNA protein plays a critical role in the production of cytokines TNF-α and IL-6, which increase inflammation throughout the body.

MGC Pharmaceuticals Co-Founder and Managing Director Roby Zomer said this was the final pre-clinical mechanism of action study and allowed MXC the opportunity to expand future trials.

“The completion of this study has advanced our understanding of the biological mechanisms and demonstrated CimetrA’s effective in the treatment of inflammatory disease, which will allow us to open the target market not only as a COVID-19 treatment but to the whole anti-Inflammatory treatments, such keeping the relevancy of CimetrA as more than just seasonal hype treatment but as long-term treatment offering,” Mr Zomer said.

Results from MXC’s latest study will form part of its application to the US Food and Drug Administration (FDA) to register CimetrA as an Investigational New Drug.

MXC shares were trading at 0.8 cents at 3:27 pm.

MXC by the numbers
More From The Market Herald

Microcap Desert Metals makes bold move into West Africa

WA-based polymetals explorer Desert Metals (ASX:DM1) has announced it's setting up shop in West Africa.

Arafura Rare Earths secures indicative financing support for Nolans project

Arafura Rare Earths (ASX:ARU) has secured a non-binding LOI from Korea EXIMbank for up to US$150…

Barton Gold wraps up resource-boosting Tunkillia drill run

Barton Gold (ASX:BGD) shares were up almost five per cent to 26 cents in the second…

The Calmer Co locks in $700k in funding via convertible note issue

The Calmer Co (ASX:CCO) has confirmed its receipt of $700,000 in funding from existing shareholders.